Acute graft-versus-host disease (GVHD) is a common immune complication that can occur
after allogeneic haematopoietic cell transplantation (alloHCT). Acute GVHD is a major …

When T cells from a bone marrow donor begin to attack the host within 3 months after
hematopoietic-cell transplantation, acute graft-versus-host disease results. The disease …

Abstract Interleukin-33 (IL-33)—a member of the IL-1 family—was originally described as an
inducer of type 2 immune responses, activating T helper 2 (TH2) cells and mast cells. Now …

Il1rl1 (also known as ST2) is a member of the IL-1 superfamily, and its only known ligand is
IL-33. ST2 exists in two forms as splice variants: a soluble form (sST2), which acts as a …

The relationship between intestinal microbiota composition and acute graft-versus-host
disease (GVHD) after allogeneic blood/marrow transplantation (allo-BMT) is not well …

Interleukin-1 (IL-1) is a central mediator of innate immunity and inflammation. The IL-1 family
includes seven ligands with agonist activity (IL-1α and IL-1β, IL-18, IL-33, IL-36α, IL-36β, IL …

Chronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality
and disability in allogeneic hematopoietic cell transplantation recipients and a major …

Transplantation-associated thrombotic microangiopathy (TA-TMA) is an increasingly
recognized complication of hematopoietic cell transplantation (HCT) associated with …

Allogeneic hematopoietic cell transplantation (allo-HCT) is an essential therapeutic modality
for patients with hematological malignancies and other blood disorders. Unfortunately, acute …

BACKGROUND. No laboratory test can predict the risk of nonrelapse mortality (NRM) or
severe graft-versus-host disease (GVHD) after hematopoietic cellular transplantation (HCT) …